- Home
- Solutions
- By Diseases
- Ocular Neoplastic Diseases
- Lacrimal Sac Adenocarcinoma (LSA)
Lacrimal Sac Adenocarcinoma (LSA) is an uncommon malignancy arising from the glandular epithelium of the lacrimal sac. With state-of-the-art platforms and an experienced team, Protheragen provides customized lacrimal sac adenocarcinoma diagnostics and therapeutic development services tailored to each client's unique needs.
Lacrimal sac adenocarcinoma arises in the lacrimal sac, a part of the tear drainage system, and is highly aggressive and rare. This neoplasm is a part of the myriad types of lacrimal sac tumors which are not common in general, with few hundred cases documented throughout the world. The limited variety of this condition makes diagnosis and management extremely challenging. As with most adenocarcinomas of the lacrimal sac, which make up 3% to 4% of epithelial tumors, these types are also associated with local invasion and metastasis, hence, early detection and therapy is very important.
Fig.1 Immunohistochemistry examination of lacrimal sac adenocarcinoma. (Takizawa D., et al., 2025)The definitive method for diagnosis confirmation of lacrimal sac adenocarcinoma is through pathologic examination, which remains histopathological analysis. Biopsy specimens are checked for distinguishing elements like cribriform pattern, the presence of duct structures, and infiltrating desmoplastic stroma. Along with these, nuclear atypia and mitotic activity are some of the additional features which are regularly seen. For methods such as Expressed Immunohistochemistry, differentiation between adenocarcinoma and other malignancies is performed using CK-7 and GCDFP-15 staining. In contrast, those markers are irreversibly positive in lacrimal sac adenocarcinomas and immunodiagnostic confirmatory.
| Therapeutics | Targets | Description | Stages |
| Abiraterone | Androgen Synthesis | Abiraterone is an androgen synthesis inhibitor that blocks the production of androgens. It is approved for the therapeutics of prostate cancer but is under investigation for its potential use in treating AR-positive lacrimal sac adenocarcinoma. It has shown promising results in some case reports. | Preclinical |
| LHRH Analogs | Pituitary Gonadotropin Release | LHRH analogs, such as leuprolide, suppress the production of gonadotropins by the pituitary gland, which in turn reduces the production of androgens. They are commonly used in combination with abiraterone to treat prostate cancer and are being investigated for their potential use in treating AR-positive lacrimal sac adenocarcinoma. | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
A multidisciplinary effort that combines modern gene editing, histopathology, molecular biology, and therapeutic innovation is essential for the development of diagnostics and therapeutics for lacrimal sac adenocarcinoma. At Protheragen, we provide full diagnostic and therapeutic development services for lacrimal sac adenocarcinoma.
Protheragen employs sophisticated cell culture systems and animal models to simulate the tumor microenvironment and assess the impact of potential therapies. If you are interested in our services, please feel free to contact us.
References
Copyright © Protheragen. All rights reserved.